Genentech announced the reintroduction of Susvimo 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States with wet, or neovascular, age-related macular degeneration, following the end of a voluntary recall. The U.S. Food and Drug Administration has approved a post-approval supplement to the Biologics License Application for Susvimo, reflecting component-level updates made to the ocular implant and refill needle. Genentech will work to make Susvimo available in the U.S. to retina specialists and their patients with wet AMD in the coming weeks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Arcus Biosciences drops 6% after Roche lung cancer failure
- Roche failure likely worst case for Arcus study, says Cantor Fitzgerald
- Genentech announces FDA approval of Vabysmo 6.0 mg single-dose prefilled syringe
- FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
- Roche says Phase II/III tiragolumab study failed in lung cancer